Department of Cardiology, Skåne University Hospital, Carl-Bertil Laurells gata 9, 214 28, Malmö, Sweden; Department of Clinical Sciences, Lund University, Jan Waldenströms gata 35, 214 28, Malmö, Sweden.
Department of Clinical Sciences, Lund University, Jan Waldenströms gata 35, 214 28, Malmö, Sweden; Department of Internal Medicine, Skåne University Hospital, Jan Waldenströms gata 11 A, 214 28, Malmö, Sweden.
Atherosclerosis. 2021 Dec;338:64-68. doi: 10.1016/j.atherosclerosis.2021.10.012. Epub 2021 Nov 1.
The precursor peptide of vasopressin, copeptin, has previously been linked to increased risk of developing diabetes mellitus, coronary artery disease and cardiovascular mortality. Whether elevated copeptin is associated with markers of atherosclerosis and arteriosclerosis in the general population is not known.
In this population-based, cross-sectional study, coronary artery calcium score (CACS), carotid-femoral pulse wave velocity (c-f PWV) and fasting plasma copeptin were measured in 5303 individuals in the Swedish cardiopulmonary bioimage study (SCAPIS). Multivariable logistic regression models were used to analyze the associations between copeptin and high CACS (>100) and high c-f PWV (>10 m/s), respectively.
The number of individuals with high CACS and c-f PWV increased across increasing tertile of copeptin (11.7%, 13.3% and 16.3% for CACS and 6.9%, 8.5% and 10.6% for c-f PWV). The top tertile of copeptin was, compared with reference tertile 1, significantly associated with both high CACS and high c-f PWV after adjustment for age, sex, hypertension, diabetes mellitus, HDL, triglycerides, BMI, smoking status, creatinine and high sensitive CRP with an odds ratio (OR) of 1.260 (95% confidence interval (CI): 1.022-1.555) for CACS and OR 1.389 (95% CI: 1.069-1.807) for PWV.
Copeptin is associated with both coronary atherosclerosis and increased arterial stiffness in the general population. Our data indicates that copeptin may be a useful marker in the assessment of cardiovascular risk.
加压素前体肽(copeptin)先前与发生糖尿病、冠状动脉疾病和心血管死亡率风险增加有关。在普通人群中,升高的 copeptin 是否与动脉粥样硬化和动脉硬化的标志物相关,目前尚不清楚。
在这项基于人群的横断面研究中,在瑞典心肺生物影像研究(SCAPIS)中测量了 5303 名个体的冠状动脉钙评分(CACS)、颈动脉-股动脉脉搏波速度(c-f PWV)和空腹血浆 copeptin。使用多变量逻辑回归模型分析了 copeptin 与高 CACS(>100)和高 c-f PWV(>10 m/s)之间的关联。
随着 copeptin 三分位值的升高,高 CACS 和高 c-f PWV 的个体数量也随之增加(CACS 分别为 11.7%、13.3%和 16.3%,c-f PWV 分别为 6.9%、8.5%和 10.6%)。与参考三分位 1 相比,在调整年龄、性别、高血压、糖尿病、高密度脂蛋白、甘油三酯、BMI、吸烟状况、肌酐和高敏 C 反应蛋白后,copeptin 的最高三分位与高 CACS 和高 c-f PWV 均显著相关,校正优势比(OR)分别为 1.260(95%可信区间[CI]:1.022-1.555)和 1.389(95%CI:1.069-1.807)。
copeptin 与普通人群的冠状动脉粥样硬化和动脉僵硬度增加均相关。我们的数据表明,copeptin 可能是评估心血管风险的有用标志物。